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Abstract
Introduction: Our purpose in conducting this study was to determine whether administration of high-dose
tranexamic acid (TA) at the time of diagnosis of postpartum haemorrhage (PPH) could reduce blood loss.
Methods: This was a randomised, controlled, multicentred, open-label trial. Women with PPH >800 mL following
vaginal delivery were randomly assigned to receive TA (loading dose 4 g over 1 hour, then infusion of 1 g/hour over
6 hours) or not. In both groups, packed red blood cells (PRBCs) and colloids could be used according to French
guidelines. The use of additional procoagulant treatments was permitted only in cases involving intractable bleeding.
The primary objective was to assess the efficacy of TA in the reduction of blood loss in women with PPH, and the
secondary objectives were the effect of TA on PPH duration, anaemia, transfusion and the need for invasive procedures.
Results: A total of 144 women fully completed the protocol (72 in each group). Blood loss between enrolment and
6 hours later was significantly lower in the TA group than in the control group (median, 173 mL; first to third quartiles,
59 to 377) than in controls (221 mL; first to third quartiles 105 to 564) (P = 0.041). In the TA group, bleeding duration
was shorter and progression to severe PPH and PRBC transfusion was less frequent than in controls (P <0 . 0 3 ) .I n v a s i v e
procedures were performed in four women in the TA group and in seven controls (P = NS). PPH stopped after only
uterotonics and PRBC transfusion in 93% of women in the TA group versus 79% of controls (P = 0.016). Mild, transient
adverse manifestations occurred more often in the TA group than in the control group (P = 0.03).
Conclusions: This study is the first to demonstrate that high-dose TA can reduce blood loss and maternal
morbidity in women with PPH. Although the study was not adequately powered to address safety issues, the
observed side effects were mild and transient. A larger international study is needed to investigate whether TA can
decrease the need for invasive procedures and reduce maternal morbidity in women with PPH.
Trial registration: Controlled Trials ISRCTN09968140.
Introduction
Postpartum haemorrhage (PPH) remains a leading cause
of early maternal death, accounting for about 300,000
deaths worldwide every year, and of morbidity related to
anaemia, blood transfusion and haemorrhage-related
ischaemic complications [1,2]. PPH is poorly predictable,
but its direct causes are mainly uterine atony, trauma to
the genital tract and retained placenta [3-5]. Accordingly,
detailed guidelines have been issued for optimal use of
obstetric interventions and uterotonic drugs [6]. In con-
trast, haemostatic abnormalities in this setting have long
been considered consequences of uncontrolled bleeding,
not deserving of early specific treatment. Thus, haemo-
static drugs are not routinely used as a first-line interven-
tion in PPH [6,7].
This concept was recently challenged by the demon-
stration of a relationship between fibrinogen decrease
and outcome [8]. At the same time, it was recognized
that extensive tissue injury can shift the haemostatic
equilibrium toward increased fibrinolysis, contributing
to coagulopathy and bleeding [9]. Antifibrinolytic agents,
mainly tranexamic acid (TA) and aprotinin, have been
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requirements in various elective surgeries [10]. More-
over, the Clinical Randomisation of an Antifibrinolytic
in Significant Haemorrhage (CRASH-2) study demon-
strated that TA safely reduces the risk of death in bleed-
ing trauma patients [11]. In the field of obstetrics, three
randomised, controlled trials [12-14] have suggested
that TA administration in women after vaginal or elec-
tive caesarean delivery reduces blood loss and the inci-
dence of PPH, with a pooled relative risk for PPH of
0.44 (95% confidence interval, 0.31 to 0.64) [15]. How-
ever, such a strategy implies that the drug must be
administered to every woman, an option that needs
careful evaluation in terms of the benefit-risk ratio
before it is widely implemented. A more efficient
approach could be to administer TA after the onset of
PPH, as recently suggested [16]. However, no study has
yet assessed the efficacy and risk of such a strategy.
Therefore, we designed a prospective, multicentred,
randomised, controlled study to analyze the effects of TA
administered intravenously at the time PPH is diagnosed.
The primary objective of the study was to assess the effi-
cacy of TA in the reduction of blood loss in PPH, while
secondary objectives were to assess the effect of TA on
(1) duration of bleeding; (2) anaemia; (3) need for inva-
sive procedures such as hysterectomy, surgical artery
ligatures and embolisation; and (4) need for transfusion.
Materials and methods
Trial framework
The trial was conducted between 2005 and 2008 in
eight French obstetric centres (five tertiary care centres
(102 patients) and three secondary care obstetric units
(50 patients). The protocol was approved by the ethics
committee of the University Hospital of Lille in June
2005 (CP05-07, CCPP nord-ouest 4, France), and data
concealment was validated by the French Commission
Informatique et Liberté (CNIL-MRO1). All pregnant
women who received prenatal care in the participating
centres were given information about this protocol dur-
ing routine third-trimester visits. The women gave their
written consent before entering the study in accordance
with the Declaration of Helsinki. This study was funded
and monitored by the French Ministry of Health (Pro-
gramme Hospitalier National de Recherche Clinique,
2004 no. 1915). The funding source approved the study
but had no role in the collection, analysis or interpreta-
tion of data; in the writing of the report; or in the deci-
sion to submit the paper for publication.
Study design and patient eligibility criteria
This academic multicentred, randomised, controlled,
open-label study evaluated the efficacy and safety of TA in
women with PPH. The design of the study is presented
Figure 1. In each participating centre, an under-buttocks
drape with a graduated collection pouch (Vygon, Ecouen,
France) was placed immediately after each vaginal delivery
to measure blood loss in the postpartum period. Overesti-
mation of blood loss because of the addition of antiseptic
or saline solutions used for washing or bladder catheteri-
zation was avoided. Midwives unaware of the group allo-
cation measured the volume of haemorrhage in the
graduated collection bag at each time point. Gauze was
strictly kept for weighing. Baseline and final blood loss
measurement were quantified and verified by weighing the
pouch and the gauze. All patients with PPH >500 mL
were managed according to the same timing according to
French practice guidelines [16]: bladder catheter, manual
removal of retained placenta, genital tract examination,
uterine exploration and oxytocin (30 U/30 minutes),
followed, and if these procedures were inefficacious, sul-
prostone was administered (500 μg in 1 hour) without any
procoagulant treatment. Patients with PPH >800 mL were
included in the study. Exclusion criteria were age <18
years, absence of informed consent, caesarean section,
presence of known haemostatic abnormalities before preg-
nancy and history of thrombosis or epilepsy.
Immediately after inclusion, patients were randomised
to receive either TA (TA group) or no antifibrinolytic
treatment (control group). The randomisation sequence
was generated by a centralized computer, and randomi-
sation was balanced by centre. In the TA group, a dose
of 4 g of TA was mixed with 50 mL of normal saline
and administered intravenously over a 1-hour period.
After the loading dose infusion, a maintenance infusion
Figure 1 Diagram showing the study design. PPH, postpartum
haemorrhage; TXA, tranexamic acid.
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This high dose was chosen as the best dose for the
reduction of bleeding in high-risk cardiac surgery
[17,18] and was administered to reduce significant active
haemorrhage of more than 800 mL the clinical course of
which might be life-threatening.
At four time points (T1 = inclusion, T2 = T1 + 30
minutes, T3 = T1 + 2 hours and T4 = T1 + 6 hours),
the graduated collection pouch was replaced and the
volume of blood loss was recorded. Blood haemoglobin
level was also measured (HemoCue; HemoCue Meaux
France). Blood samples were collected and tested for
haemoglobin concentration and hematocrit. Bleeding
was considered to have stopped when the flow was
<50 mL/10 minutes.
In both study groups, packed red blood cells (PRBCs) and
colloids could be used according to French guidelines. Vas-
cular loading was as follows: crystalloid Ringer’s lactate
solution (Macoflex; Boulogne Billancourt, France) (500 mL)
and the gelatin plasma expander Gelofusine 4% (B-Braun
Medical, Boulogne Billancourt, France) (500 mL) for the
first bleeding litre, then an infusion of gelatin was adminis-
tered to compensate for blood loss (vol/vol). When blood
loss exceeded 2,500 mL, loading was partially supported by
an infusion of fresh frozen plasma (FFP). According to
French guidelines, infusion of PRBCs was indicated when
the patient’s haemoglobin level was <8 g/dL.
In both study groups, the use of additional procoagulant
treatment (FFP, platelets and fibrinogen concentrate) was
not permitted before T3. However, at any time in both
groups, additional procoagulant treatments or invasive
procedures could be used in cases of intractable bleeding
(PPH >2,500 mL or blood flow >500 mL/30 minutes).
According to national guidelines, postpartum thrombo-
prophylaxis was carried out with low-molecular-weight
heparin 50 IU/kg/day in the patients in severe condition in
both groups from day 1 until the inflammatory syndrome
disappeared.
Criteria for evaluation
The primary end point was the volume of blood loss
between T1 and T4. Secondary end points were duration
of bleeding and the impact of TA on PPH-related out-
come (decrease in haemoglobin concentration; transfu-
sion of PRBCs at T4 and at day 42; and the need for
invasive procedures (uterine artery embolisation or liga-
ture, hysterectomy), late postpartum curettage or general
o u t c o m e( i n t e n s i v ec a r eu n i ts t a y ,u s eo fa n yv a s o p r e s -
sors, dyspnoea, renal and multiple organ failure)). Severe
PPH was defined by Charbit et al. [8] as exhibiting one of
the following criteria: peripartum decrease of haemoglo-
bin >4 g/dL, with the last haemoglobin value before
delivery considered as the reference; transfusion of at
least 4 U of PRBCs; invasive haemostatic intervention; or
death. Evaluation of each end point was performed by
investigators blinded to treatment allocation.
Side effects
Although this study was not powered to address safety
issues, side effects that could be related to TA were ana-
lyzed. Major side effects (thrombotic events, renal failure
or seizures) and minor side effects were reported at each
time point and at day 42. With respect to venous throm-
bosis, clinical signs of superficial or deep thrombosis
were collected, and ultrasonography was performed as
soon as the signs were detected.
Sample size calculation
In a preliminary study, the mean ± standard deviation (SD)
volume of PPH observed at T4 was 1,340 mL ± 490 mL.
To demonstrate a decrease of 20% in the volume of PPH
in the TA group, the number of patients had to be 144 for
at y p eIe r r o ro f5 %a n dap o w e ro f9 0 %[ 1 2 ] .
Statistical methods
Anonymous data were managed by an independent
operator (Altizem, Nanterre, France) after double data
acquisition. Results are expressed as means ± SD in cases
of normal distribution and as medians and interquartile
ranges otherwise. The normality of the distributions was
tested using the Shapiro-Wilk test. Comparisons between
groups were performed using the c
2 test or Fisher’s exact
test for categorical variables. For numerical variables, we
used Student’s t-test in cases of normal distribution and
the Mann-Whitney U test otherwise. All analyses invol-
ving the volumes of PPH were adjusted for the volume of
blood loss between birth and T1 and for the centre. Since
the distributions of the volumes of PPH were not normal,
these parameters were analyzed using the nonparametric
procedure recommended by Conover and Iman [19]. For
the primary end point, comparison between the two
groups was performed using covariance analysis. The
time course of blood loss was studied using analysis of
variance for repeated measurements. Post hoc analyses
were performed using the Bonferroni correction. For the
primary objective, analyses were performed both per pro-
tocol and on an intention-to-treat (ITT) basis. The dura-
tion of bleeding was analyzed by using the Kaplan-Meier
method and compared across groups by using the log-
rank test. All statistical analyses were performed using
SAS software (SAS Institute, Cary, NC, USA). A P value
< 0.05 was considered statistically significant.
Results
Among 154 women who were eligible for inclusion, 2 did
not agree to be included, so 152 were included. Among
them, one woman was later found not to meet the inclu-
sion criteria and seven other women (n =5i nt h eT A
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tions (inappropriate infusion of additional procoagulant
treatments, such as FFP, fibrinogen concentrate, aproti-
nin or a large amount of PRBCs before T3 in the absence
of intractable haemorrhage). Therefore, 144 women fully
completed the protocol (72 in the control group and 72
in the TA group). All included women, apart from the
one who did not meet the inclusion criteria, were
included in the ITT analysis (Figure 2).
Anthropomorphic, obstetric and anaesthetic character-
istics (Table 1), as well as PPH management (Table 2),
were not significantly different between the two groups.
There were no site-specific differences in any variables
presented between the centres.
At the time of patients’ inclusion (T1), blood loss did
not differ between the two groups (median values of
1,000 mL (first to third quartiles, 840 to 1,110) in the TA
group and 950 mL (first to third quartiles, 800 to 1,100 in
the control group) (P = 0.96). The volume of each
patient’s blood loss in the two groups is shown Figure 3.
The blood loss between T1 and T4 was significantly
lower in the TA group (median, 170 mL (first to third
quartiles, 58 to 323)) than in the control group (median,
221 mL (first to third quartiles, 110 to 543) (P = 0.041).
The duration of bleeding was lower in the TA group
than in the control group (P = 0.004; logrank test)
(Figure 4). Bleeding was stopped by T2 in 63% of
w o m e ni nt h eT Ag r o u pa n di n4 6 %o fw o m e ni nt h e
control group (P = 0.034).
Because the time course of bleeding appeared to differ
significantly after T2, we analyzed the volume of blood
loss from T2 to T4. Between T2 and T4, blood loss was
49% lower in the TA group (median, 39 mL (first to
third quartile, 2 to 101)) than in the control group
(median, 77 mL (first to third quartile, 15 to 185)) (P =
0.03 after Bonferroni correction) (Figure 5).
The time at which invasive procedures were performed
is shown in Figure 4. Haemostatic embolisation was per-
formed in five women in the TA group and in five women
in the control group (P = 0.94) after a median PPH dura-
tion of 110 minutes (range, 30 to 155 minutes) in the TA
group and 140 minutes (range, 75 to 315 minutes) in the
control group. Hysterectomy or surgical uterine artery
ligature was performed in two women in the control
group at 315 minutes and 525 minutes, respectively, and
in none in the TA group.
PPH-related outcome ITT and per protocol analysis
are both presented in Table 3. There was a trend
toward a decrease in incidence of severe PPH in ITT
analysis that was significant in per protocol analysis.
The incidence of decrease in haemoglobin concentra-
tion of more than 4 g/dL, as well as the number of
PRBCs transfused before day 42, was significantly
l o w e ri nt h eT Ag r o u pt h a ni nt h ec o n t r o lg r o u pi n
both analyses.
Overall, PPH reached the criteria for severity in
27 women in the TA group and in 37 women in the con-
trol group (P = 0.028). The subgroup of women who
experienced severe PPH was not different from those who
did not experience severe PPH with respect to anthropo-
morphic and obstetric characteristics, except for baseline
volume of bleeding, which was significantly higher at T1
(median, 1,000 mL (first to third quartile, 870 to 1,200) in
women with severe PPH vs. 900 mL (first to third quartile,
800 to 1,100) in women without severe PPH (P =0 . 0 3 8 ) .
In those women with severe PPH, (1) haemorrhage dura-
tion was shorter in the TA group than in the control
group (median 30 minutes (first to third quartile, 15 to
40 minutes) vs. median 30 minutes (first to third quartile,
20 to 93 minutes) (P = 0.001), and (2) in the PPH popula-
tion, one woman in the TA group and seven women in
the control group received procoagulant drugs (fibrinogen
Figure 2 Diagram showing the study profile. ITT, intention to treat; FFP, fresh frozen plasma.
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tice guidelines and study design (P =0 . 0 0 1 ) .
Overall, PPH stopped after administration of utero-
tonic drugs and PRBC support and without any appro-
priate haemostatic drug (other than TA in the TA
group ) in 57 women (79%) in the control group and in
67 women (93%) in the TA group (P = 0.016).
The only severe adverse manifestations were deep vein
thrombosis at the site of the venous catheter, which
occurred in two patients in the TA group and in one in
the control group (P = 0.375) (Table 4). Urea, creatinine-
mia, and diuresis at T4 did not differ between the two
groups. Mild transient adverse manifestations (nausea,
vomiting, dizziness and phosphenes) occurred more
often in the TA group (n = 18) than in the control group
(n =4 )( P = 0.03) (Table 4). No seizures and no maternal
deaths occurred in either group.
Discussion
This study demonstrates for the first time that TA
administered to women with overt PPH decreases blood
loss, bleeding duration and maternal morbidity with
only minor, transient side effects. In addition, TA-trea-
ted women received fewer additional procoagulant treat-
ments, such as FFP, platelets and fibrinogen.
PPH definition and blood loss measurement
PPH is usually defined as blood loss >500 mL after vagi-
nal haemorrhage [13,15], but it was defined as ≥400 mL
blood loss in the studies by Gay et al. [12] and Yang
et al. [14]. In the present study, we chose to include
women who had blood loss >800 mL to select women
with a high risk of severe PPH, thereby strengthening
our results. Another important strength of this study is
the careful and homogeneous measurement of blood
loss in each participant using specially designed under-
buttocks drapes with a graduated collection pouch that
accurately evaluates small volumes. This measurement
was completed by weighing the pouch and compresses.
We also established a definition of bleeding flow to
align the criteria for obstetric and intensive care deci-
sions at each step of the procedure.
Table 1 Maternal and obstetric characteristics
a
Group TA Control P value
Number of patients 72 72
Mean age, yr (± SD) 29 (4) 28 (5) 0.55
Mean weight, kg (± SD) 67 (16) 65 (12) 0.54
Mean height, cm (± SD) 164 (5) 165 (6) 0.18
Parity: primiparae, n (%) 46 (64) 50 (69) 0.06
Mean gestational age, weeks (± SD) 39.5 (2) 39.5 (1.8) 0.97
Twin pregnancies, n (%) 4 (6) 3 (4) 0.6
Abnormal placental insertion, n (%) 2 (3) 3 (4) 0.8
Oxytocin for labour induction, n (%) 9 (12) 12 (17) 0.88
Mean labour duration, hours (± SD) 6 (3) 6 (3) 0.82
Epidural analgesia, n (%) 59 (82) 61 (84) 0.45
Instrumental delivery, n (%) 7 (9) 10 (14) 0.85
Oxytocin at delivery, n (%) 30 (42) 31 (42) 0.89
Mean newborn weight, g (± SD) 3,475 (610) 3,489 (526) 0.89
Mean minutes between delivery and inclusion (± SD) 56 (49) 44 (41) 0.39
Atony-related PPH, n (%) 54 (75) 50 (69) 0.41
aSD, standard deviation; PPH, postpartum haemorrhage; TA, tranexamic acid. a risk: P < 0.05 using c
2 test or the Fisher’s exact test for categorical variables.
Student’s t-test was used in cases of normal distribution; otherwise, the Mann-Whitney U test was used for numerical variables.
Table 2 PPH management
a
Group TA Control P value
Number of patients 72 72
Mean crystalloid loading at T3, mL (± SD) 934 (575) 949 (712) 0.54
Mean colloid loading at T3, mL (± SD) 611 (500) 736 (459) 0.13
Mean total loading volume, mL, (± SD) 1,547 (722) 1,672 (787) 0.36
Prostaglandins for PPH, n (%) 36 (48) 34 (43) 0.74
Postpartum thromboprophylaxis, n (%) 16 (22) 14 (20) 0.8
aPPH, postpartum haemorrhage; TA, tranexamic acid; T3, 2 hours after inclusion. a risk: P < 0.05 using the c
2 test or Fisher’s exact test for categorical variables.
Student’s t-test was used in cases of normal distribution, and otherwise the Mann-Whitney U test was used for numerical variables.
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TA was chosen because it has been demonstrated to be
a potent antifibrinolytic agent in elective surgical
patients and because it is the most often used antifibri-
nolytic agent worldwide. TA has the additional advan-
tage of being inexpensive and easy to stock and handle
[10]. It remains the only antifibrinolytic agent available
in France at present.
Given the lack of previous studies on PPH, we chose a
fixed-dose regimen, which, given the weight of the parti-
cipants, was, on average, a 60 mg/kg loading dose fol-
lowed by a 16 mg/kg/hour infusion.
T h eh i g hd o s eo f4g+6g( 6 0m g / k ga sal o a d i n g
dose followed by a 16 mg/kg/hour infusion) TA was
chosen in our study as the best clinically effective dose
used to reduce haemorrhage in high-risk cardiac surgery
patients [17,18,20,21]. At the beginning of the study,
these were the only data available on active doses in
reducing haemorrhage. This high dose has been used
successfully since 2004 in high-risk cardiac surgery [21].
The purpose of this study was to investigate the poten-
tial for reducing bleeding by administering TA in women
with active PPH. The studied population was selected on
the basis of active haemorrhage of more than 800 mL
Figure 3 Bar graph illustrating blood loss between T1 and T4 (from the smallest to the largest) for each woman in the two groups.
Black bars = TA group, white bars = control group. The y-axis represents the volume of blood loss (in millilitres) between T1 and T4. The x-axis
values are the rank of each woman according to the amount of blood loss.
Figure 4 Graph showing time from enrolment until PPH cessation in the two groups. Solid line = TA group, dashed line = control group.
P = 0.003 using the Kaplan-Meier logrank test. Time points of the study (T2 = T1 + 30 minutes, T3 = T1 + 2 hours, T4 = T1 + 6 hours) are
indicated on the x-axis. The time of each invasive procedure is indicated by an arrow.
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unusual 800-mL threshold for the definition of PPH,
rather than 500 mL, was selected for active PPH. This
selection of patients required a specific procedure for
measurement and verification of blood loss at each time
point.
Since then, the BART study in 2008 [22] and the
CRASH-2 study in 2010 [11] have used lower doses of
T A( 3 0m g / k g+1 6m g / k g / h o u ra n d1g+1g ,r e s p e c -
tively). In the BART study, patients were selected for
their potential for high blood loss estimated on the basis
of their risk of requiring surgery. In the CRASH-2
study, the patients were selected as patients “experien-
cing or considered to be at risk of significant haemor-
rhage” [11]. These studies’ lower doses were designed to
limit bleeding in a large and less selective population
than that in our study.
Clinical relevance of the results
The observed reduction in blood loss, although signifi-
cant, was modest in terms of median values. Nonethe-
less, the time course of blood loss clearly suggests that
TA prevented the onset of severe or intractable bleeding
in some women. This suggestion was confirmed by the
observation that the number of severe PPH cases was
Figure 5 Graph illustrating blood loss between T2 and T4
between the two groups. P = 0.04 using the Mann-Whitney U test
after applying the Bonferroni correction.
Table 3 Assessment of PPH-related outcome
a
Group TA Control P value
Number of patients
ITT 77 74
Per protocol 72 72
Evolution to severe PPH, n (%)
ITT 27 (35) 37 (50) 0.07
Per protocol 23 (32) 36 (50) 0.028
Persistent bleeding at T2, n (%)
ITT 28 (36) 40 (54) 0.03
Per protocol 26 (36) 38 (53) 0.044
Haemoglobin drop >4 g/dL, n (%)
ITT 19 (25) 32 (43) 0.02
Per protocol 15 (21) 34 (47) < 0.001
PRBC transfusion before T4, n (%)
ITT 10 (13) 13 (18) 0.17
Per protocol 7 (10) 12 (17) 0.65
PRBC units administered before T4, n
ITT 32 62 0.26
Per protocol 18 38 0.4
PRBC transfusion total through day 42,
n (%)
ITT 13 (17) 20 (27) 0.33
Per protocol 9 (13) 20 (28) 0.16
PRBC units administered total through
day 42, n
ITT 28 62 < 0.001
Per protocol 24 62 < 0.001
Table 3 Assessment of PPH-related outcome
a (Continued)
Arterial embolisation, n (%)
ITT 5 (6.8) 5.1 (6.1) 1
Per protocol 4 (6.0) 5 (7.0) 0.73
Surgical arterial ligature or
hysterectomy, n (%)
ITT 0 2 (2.7) 0.24
Per protocol 0 2 (3.0) 0.5
Late postpartum curettage (after day 7),
n (%)
ITT 1 (1.3) 2 (2.7) 1
Per protocol 1 (1.4) 2 (2.8) 1
Any vasopressor, n (%)
ITT 4 (5.2) 4 (5.4) 1
Per protocol 3 (4.2) 4 (5.5) 1
Intensive care unit stay, n (%)
ITT 3 (3.9) 5 (6.7) 1
Per protocol 3 (4.2) 5 (7.0) 1
Mild dyspnea, n (%)
ITT 0 (0) 1 (1.3) 1
Per protocol 0 (0) 1 (1.4) 1
Multiple organ failure, n (%)
ITT 0 (0) 0 (0) -
Per protocol 0 (0) 0 (0) -
aPPH, postpartum haemorrhage; TA, tranexamic acid; ITT, intention to treat;
PRBC, packed red blood cell. a risk: P < 0.05 using the c
2 test or Fisher’s exact
test for categorical variables. Student’s t-test was used in cases of normal
distribution, and otherwise the Mann-Whitney U test was used for numerical
variables.
Ducloy-Bouthors et al. Critical Care 2011, 15:R117
http://ccforum.com/content/15/2/R117
Page 7 of 10l o w e ri nt h eT Ag r o u pt h a ni nt h ec o n t r o lg r o u p .T h e
decrease in haemoglobin concentration and the need for
blood transfusions were also reduced in the TA group.
Finally, PPH stopped without administration of haemo-
static drugs or invasive procedures in 93% of TA-treated
women, but in only 80% of women in the control group.
Therefore, we conclude that the mild effect of TA on
median blood loss is clinically relevant and that TA may
have prevented the need for procoagulant drugs or inva-
sive procedures in up to 13% of women. An additional
consequence of the decrease in maternal morbidity asso-
ciated with TA is the potential to spare medical costs.
Side effects
As in previous studies [10,11,22,23], no alteration of
renal function was observed. Although this study was
not powered to address safety issues, the only side
effects we recorded were gastrointestinal and neurologi-
cal manifestations as previously described [24,25], which
were mild and reversible but were more frequent in the
TA group than in the control group. We observed two
cases of thrombosis in the TA group and one in the
control group after complicated delivery and after TA
treatment; however, the design of the study did not
allow for a definite conclusion on the risk of thrombosis
related to TA in this setting. That the high-dose regi-
men is responsible for the increased rate of side effects
in the TA group remains possible.
Potential limitations
First, the major weakness of this randomised, controlled
study is its open-label, unblinded character. Therefore,
the results are at risk of bias. This design was chosen to
limit the budget, which was supported only by academic
funding, and because of the restricted number of parame-
dics and medical teams available for PPH management,
especially during on-call periods. However, centralized
randomisation and strict data concealment were fol-
lowed. Moreover, the anaesthesiologist performed rando-
misation and also immediately administrated (or not) the
treatment. Although the study was not blinded, obstetri-
cians and midwives were not aware of the treatment
group, so the rest of the management, blood loss mea-
surement and transfusion algorithm were conducted
regardless of the group allocation. Finally, statistical ana-
lyses were performed on an ITT basis.
A second limitation is that the design of this study was
not powered to show decreases in maternal death or
number of invasive procedures, which are the ultimate
goals of maternity treatment. Nevertheless, we observed a
trend toward a decrease in the rate of PPH embolisation
and surgical procedures. From this perspective, the study
produced encouraging data that support the need for
further work, such as the recently launched WOMAN
trial [26], to assess the most important issues related to
the reduction of maternal mortality.
Third, the TA-related risk of thrombosis evaluation
could not be evaluated in this study, as deep vein
thrombosis was only diagnosed clinically and confirmed
by Doppler ultrasound. Twenty-two of the patients in
each group were treated with thromboprophylaxis, as
recommended for the PPH inflammatory syndrome. The
Table 4 Side effects of treatment
a
Group TA Control P value
Number of patients
ITT 77 74
Per protocol 72 72
Severe side effects
Deep vein thrombosis, n (%)
ITT 2 (3) 1 (1) 0.4
Per protocol 2 (3) 1 (1) 0.37
Renal failure, n (%)
ITT 0 (0) 0 (0) -
Per protocol 0 (0) 0 (0) -
Mean T4 urea, g/L (± SD)
ITT 0.17 (0.06) 0.2 (0.1) 0.9
Per protocol 0.1 (0.1) 0.2 (0.1) 0.9
Mean T4 creatininemia,
mg/L (± SD)
ITT 6.3 (1.8) 6.4 (1.7) 0.79
Per protocol 5.4 (2.8) 6.0 (2.3) 0.7
Mean T4 diuresis, mL (± SD)
ITT 1,058 (1,010) 882 (480) 0.25
Per protocol 1,044 (933) 862 (575) 0.23
Seizures, n (%)
ITT 0 (0) 0 (0) -
Per protocol 0 (0) 0 (0) -
Maternal death, n (%)
ITT 0 (0) 0 (0) -
Per protocol 0 (0) 0 (0) -
Nonsevere side effects
Nausea/vomiting, n (%)
ITT 12 (15) 1 (2) 0.002
Per protocol 11 (15) 1 (2) 0.002
Phosphenes, n (%)
ITT 9 (12) 2 (3) 0.02
Per protocol 8 (11) 2 (3) 0.02
Dizziness, n (%)
ITT 4 (5) 3 (4) 0.28
Per protocol 4 (6) 3 (4) 0.28
Total nonsevere adverse effects,
n (%)
ITT 18 (23) 4 (6) 0.03
Per protocol 17 (24) 4 (6) 0.03
aTA, tranexamic acid; ITT, intention to treat. a risk: P < 0.05 using the c
2 test
or Fisher’s exact test for categorical variables. Student’s t-test was used in
cases of normal distribution, and otherwise the Mann-Whitney U test was
used for numerical variables.
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sion regarding the risk of thrombosis related to TA in
this setting.
Fourth, our study was performed in tertiary care and
secondary care women’s hospitals in a high-income
country, which allowed for optimal obstetrical manage-
ment. Whether these results can be reproduced in a
suboptimal environment remains to be demonstrated.
This factor is important to consider, since TA has the
clear advantage of being an inexpensive, stable, off-the-
shelf, easy-to-use drug, even in low-income countries.
Conclusions
This study is the first to demonstrate that TA can
reduce blood loss and maternal morbidity in ongoing
PPH. Adverse effects were only mild and transient, even
at the relatively high doses used, but the study was not
powered to address safety issues. These encouraging
data strongly support the need for a large, international,
double-blind study to investigate the potential of TA to
reduce maternal morbidity worldwide.
Key messages
￿ We conducted a randomised, controlled study of
144 patients with the purpose of appreciating the
effect of a high dose of intravenous tranexamic acid
on strictly measured PPH volume.
￿ This study was conducted in eight French obste-
trics units in accordance with French PPH treatment
guidelines and was funded and monitored by public
health academic support.
￿ We observed a significant reduction of blood loss,
evolution to severe PPH, haemoglobin drop >4 g/dL,
and a reduced number of PRBCs transfused before
day 42.
￿ This study represents the first demonstration that
antifibrinolytic treatment can decrease blood loss
and maternal morbidity in women with PPH, which
is a leading cause of maternal death.
￿ This study supports the need for a large interna-
tional study to investigate the potential of TA, a sim-
ple and inexpensive treatment, to reduce maternal
morbidity worldwide.
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